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Aim: In measuring exit ﬂuences, there are several sources of deviations which include the
changes in the entrance ﬂuence, changes in the detector response and patient orientation
or  geometry. The purpose of this work is to quantify these sources of errors.
Background: The use of the volumetric modulated arc therapy treatment with the help of
image guidance in radiotherapy results in high accuracy of delivering complex dose distri-
butions while sparing critical organs. The transit dosimetry has the potential of Verifying
dose delivery by the linac, Multileaf collimator positional accuracy and the calculation of
dose  to a patient or phantom.
Materials and methods: The quantiﬁcation of errors caused by a machine delivery is done by
comparing static and arc picket fence test for 30 days. A RapidArc plan, created for the pelvis
site  was delivered without and with Rando phantom and exit portal images were acquired.
The day to day dose variation were analysed by comparing the daily exit dose images during
the course of treatment. The gamma criterion used for analysis is 3% dose difference and
3  mm distance to agreement with a threshold of 10% of maximum dose.
Results: The maximum standard deviation for the static and arc picket fence test ﬁelds were
0.19  CU and 1.3 CU, respectively. The delivery of the RapidArc plans without a phantom
shows the maximum standard deviation of 1.85 CU and the maximum gamma value of 0.59.
The maximum gamma value for the RapidArc plan delivered with the phantom was found
to  be 1.2. The largest observed ﬂuence deviation during the delivery to patient was 5.7% andthe  maximum standard deviation was 4.1 CU.
Conclusion: It is found from this study that the variation due to patient anatomy and inter-
fraction organ motion is signiﬁcant.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All∗ Corresponding author at: No. 46 Manimegali Street, East Tambaram, C
E-mail address: prabakarsukumar@gmail.com (P. Sukumar).
1507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2012.06.003rights reserved.hennai 600 059, Tamil Nadu, India. Tel.: +91 9789882591.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
radio
1
T
m
i
w
s
a
d
d
d
p
i
d
t
t
l
t
c
p
d
o
E
c
a
i
u
a
o
e
o
I
d
f
d
a
n
t
2
T
a
p
o
e
d
3
T
2
1
i
(
areports of practical oncology and 
.  Background
he use of the volumetric modulated arc therapy (VMAT) treat-
ent with the help of image  guidance in radiotherapy results
n high accuracy of delivering complex dose distributions
hile sparing critical organs. This treatment technique neces-
itates two or three dimensional (3D) patient speciﬁc quality
ssurance to deliver the dose accurately. Many  articles1–3
escribed the advantages of the electronic portal imaging
evice (EPID) as potential for in vivo measurements, point
ose measurements and 3D dose veriﬁcation. The transit (or)
rojection and non-transit dosimetry are the two categories
n the dosimetric veriﬁcation using the EPID. The non-transit
osimetry is extensively used for the pre-treatment veriﬁca-
ion without a patient or phantom. The transit dosimetry has
he potential of verifying dose delivery by the linac, multi-
eaf collimator positional accuracy and the calculation of dose
o a patient or phantom. There has been reports in literature
omparing exit ﬂuences with predicted ones4–9 and also com-
aring back projected and reconstructed dose with a planned
ose distribution within the patient.10–13 A literature review
f the portal imager and dosimetry were described by Van
lmpt et al.14 The integrated images of portal dosimetry were
orrected by General Linear Calibration of the imager (GLAaS)
lgorithm to convert images to absolute dose measurements
n phantom.15 The 3D dose veriﬁcation in VMAT was done
sing gantry angle resolved acquisition or in continuous mode
cquisition.16
In measuring the exit ﬂuences, there are several sources
f deviations, which include changes in the entrance ﬂu-
nce, changes in the detector response and patient orientation
r geometry. The magnitude of these deviations during the
ntensity Modulated Radiotherapy (IMRT) treatment has been
ocumented.17 The RapidArc® which is a commercial name
or VMAT  by Varian, enables IMRT-like dose distributions to be
elivered using a single and/or multiple rotation of the gantry.
The sources of the variation were isolated in this work
nd we  investigated the exit ﬂuences by evaluating the mag-
itude of interfractional dose variation during the RapidArc
reatment for pelvic cases.
. Aim
he purpose of the work is to quantify the exit ﬂuence vari-
tion during VMAT  delivery due to errors in MLC, gantry
osition and due to patient geometrical and interfractional
rgan motion. The acquisition and analysis of exit ﬂuence for
ach fraction is useful in determining the variation in daily
elivered dose and to modify the treatment plan adaptively.
.  Materials  and  methods
he delivery system used in this study was Varian CLINAC
100 (Varian Medical Systems, Palo Alto, CA) equipped with a
20-leaf Millenium multi-leaf collimator (MLC) and on-board
mager (OBI). A portal imager, amorphous silicon aS1000 EPID
IDU 20 model, Varian Medical Systems, Palo Alto, CA) with
n active area of 40 cm × 30 cm consisting of 1024 × 768 pixelstherapy 1 7 ( 2 0 1 2 ) 324–331 325
which is attached to the machine by Exact arm (E arm) was
used to measure the exit ﬂuence. The image  acquisition soft-
ware (IAS3) provides several modes for acquisition. Integrated
mode of acquisition is calibrated using a dark ﬁeld and ﬂood
ﬁeld for 6 MV X-rays. The dark ﬁeld is corrects leakage charges
produced in the imager and the ﬂood ﬁeld corrects the sen-
sitivity of the imager pixels. The dosimetric calibration was
done such that calibration unit (CU) 1 CU = 1 cGy.
This study investigated the daily variations of (1) machine
output, (2) MLC  positioning, (3) RapidArc ﬂuence, (4) set-up
variation and (5) interfractional organ motion. The ﬁrst three
are machine related sources of variations and the other two
are the patient induced ﬂuence variability.
3.1.  Machine  stability
Daily portal images were acquired for the ﬁeld size of
10 cm × 10 cm at the source to detector distance (SDD) of
100 cm for 100 monitor units (MU). The dose rate was
300 MU/min which is being routinely used in clinical situations
for conformal and IMRT treatments. In RapidArc, the dose
rate varies from 100 MU/min to 600 MU/min. The variation in
the dose is found to be less than 2% as in a previous study.18
The variation obtained was a combination of the accelerator
output and the pixel sensitivity. To eliminate the accelera-
tor output variation, images were acquired daily after ﬂood
ﬁeld calibration. Flood ﬁeld calibration eliminates the daily
accelerator output variation. The variations in calibrated units
without and with Flood ﬁeld calibration were analysed over a
period of six weeks.
The picket fence test was performed in a static gantry to
analyse the ﬂuence variation due to MLC positions at SDD
of 150 cm.  The picket fence is formed of 1 mm wide regions
with high intensity in every 1.5 cm.  From the picket fence
test, the ﬂuence variation due to MLC positioning was deter-
mined. To quantify the variation due to gantry rotation and
MLC  positioning, arc picket fence test was delivered and por-
tal dose images were acquired at the same SDD. The variation
in ﬂuence will be a combination of errors in Gantry and MLC
positioning and pixel sensitivity. These tests were performed
for a period of six weeks and analysed.
. The standard deviation for the arc Picket fence test was
calculated in each pixel and a graph was plotted (Fig. 2
3.2.  Phantom  study
A clinical RapidArc plan for the pelvis site of a patient (P1) was
delivered without and with phantom. The test was done for
all the ﬁve plans which resulted in negligible variation. This
may be due to the fact that all the ﬁve patients had carcinoma
of Uterine Cervix of same stage and all had similar RapidArc
plans. Hence, the plan P1 is taken for quantifying the variation
in patient positioning and MLC, Gantry positions. The portal
dose images were acquired during delivery at SDD  of 150 cm.
The portal dose images acquired without phantom quantiﬁed
the variations due to MLC  and gantry positions in RapidArc
plan.
Computed Tomographic (CT) images were acquired for
Anthromorphic (Rando) phantom with 3 mm slice thickness.
A veriﬁcation plan for RapidArc was generated using Rando
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Fig. 3 – Standard deviation without and with phantom.
sion 8.6).Fig. 1 – EPID image of arc picket fence.
phantom. Correct phantom position was veriﬁed using ortho-
gonal kV images using OBI and delivered exit ﬂuences were
recorded. Apart from the gantry and MLC  positional errors, the
variation in measured exit ﬂuences includes a setup error. The
portal dose images without and with phantom were measured
over a period of six weeks.
3.3.  Variations  due  to  interfractional  organ  motion
To examine the interfractional anatomical variation, exit
ﬂuences were measured for the patients during RapidArc
treatment. Five patients (P1, P2, P3, P4, and P5) with carcinoma
of the uterine cervix with same staging were included for the
study. The double arc plans were created with clockwise (CW)
and counter clockwise (CCW) arcs from gantry angles ran-
ging from 181.1 to 179.9 (A1) and 179.9 to 181.1 (A2) degrees,
respectively, with a collimator angle of 45◦. Each plan was
also veriﬁed by the patient speciﬁc quality assurance with the
PTW 2D Ionisation chamber array and Octavious phantom,
which shows the area failing the gamma value, is less than 5%.
Fig. 2 – Standard deviation arc picket fence.Before treatment, the patient treatment position was veriﬁed
by matching the orthogonal kV images with DRR images.
For the phantom and patient study, the standard deviations
(SD) were calculated at each pixel for thirty and twenty-ﬁve
fractions, respectively. Each day variation in exit ﬂuence was
plotted with the standard deviation between the correspond-
ing pixels in each fraction in the abscissa and the number
of pixels experiencing the standard deviation in the ordinate.
First fraction portal image  was used as a reference image.  The
daily portal image  were compared with the reference image
using the gamma analysis method with criterion 3% dose dif-
ference and 3 mm distance to agreement with a threshold
value of 10% of maximum value.19–22 The maximum gamma
value and percentage area of gamma failing were analysed for
the active area of detector (30 cm × 40 cm). The portal vision
software of Eclipse planning system (Varian Medical Systems,
Palo Alto, CA) was used for the comparison of the images (ver-Fig. 4 – Maximum gamma  values for period of 30 fractions
with and without phantom.
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Fig. 5 – Standard deviation between pixels for patients.
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p.  Results
he calibration unit variation for open ﬁeld was observed over
 period of thirty days without and with ﬂood ﬁeld calibration.
he CU was measured over 10 × 10 pixel area and a maximum
ariation obtained without and with ﬂood calibration was 1.5%
nd 0.6%, respectively.
The maximum standard deviation for static Picket fence
n each pixel was 0.19 CU and showed a maximum gamma
alue of 1.61. The maximum area failing gamma criterion was
.03%. The image  of the arc picket fence test is shown in the
ig. 1). The maximum standard deviation observed in a single
ixel was 1.3 CU and maximum gamma value was 3.3. Themaximum area failing the gamma criteria was 0.1% over a
period of six weeks.
When measuring the ﬂuence without phantom or patient,
the maximum standard deviation (Fig. 3) was 1.8 CU which
occurred in 11 pixels and the maximum gamma value was 0.59
(Fig. 4). The maximum gamma  value plotted against fraction
number is shown in the Fig. 4. The maximum gamma values
were increased for the images acquired with the Rando phan-
tom compared to those acquired without phantom, which is
due to scatter from the patient and couch. The maximum
standard deviation and maximum gamma  value over a period
of thirty fractions were 1.1 CU (Fig. 3) and 1.2 (Fig. 4), respec-
tively. The area failing the gamma  criterion was less than 0.5%
in overall fractions.
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ea failing gamma  criteria.
Table 1 – Average of ave with standard deviation for
patients, phantom and without phantom.
Plan CCW CW
Picket fence test 0.1330 ± 0.0205
Without phantom 0.0700 ± 0.0181 0.0646 ± 0.0169
With phantom 0.1151 ± 0.0179 0.0131 ± 0.0153
P1 0.1251 ± 0.0265 0.1373 ± 0.0227
P2 0.1515 ± 0.0461 0.1485 ± 0.0421
P3 0.2636 ± 0.1288 0.2456 ± 0.1202
P4 0.2172 ± 0.0683 0.1988 ± 0.0552Fig. 6 – Percentage ar
For patient study, the area of gamma  failing was more  sig-
niﬁcant than the maximum gamma  values. Fig. 5 represents
the standard deviation for patients between the pixels for
twenty-ﬁve fractions and Fig. 6 represents the area of Gamma
failing for patients. Since the gamma  values show large differ-
ences in each patient, scale on Y axis vary for the purpose of
clarity. The average of the Gamma  average was tabulated for
picket fence, without phantom, phantom and patient plans
(Table 1). The maximum gamma  values for patients were plot-
ted against the fraction number (Fig. 7). For the ﬁrst patient (P1)
the maximum gamma  values were less than 2 for a period of
twenty ﬁve days. For the measurements of exit ﬂuence with
patients, the maximum area failing the gamma  criteria wereP5 0.1083 ± 0.0112 0.1054 ± 0.0163
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ound to be 5.7% and the maximum standard deviation was
.1 CU (Fig. 8). It is found that, among ﬁve patients the area fail-
ng gamma criteria was more  than 2% for patient 3. The area
ailing gamma criteria are pronounced due to interfractional
natomical variations.. Discussion
ardner et al. has stated the maximum variation in exit ﬂu-
nce due to a linear accelerator and patient’s anatomical values for patients.
changes are about 4% and 9%, respectively in IMRT  treatments.
In this study, the exit ﬂuence variation due to machine and
patients related errors were studied for RapidArc treatments.
The sources of variation due to linear accelerator, such as por-
tal imager sensitivity and MLC at different gantry positioning
were quantiﬁed. The patient related interfractional exit ﬂu-
ence variation due to setup error and anatomical changes
were quantiﬁed using Rando phantom and patients exit doses
images. From the graphs plotted, the deviations due to the
machine related sources were less than 0.6 gamma value.
The maximum gamma  value observed was 1.18 when the
330  reports of practical oncology and rad
Fig. 8 – Maximum standard deviation and maximum
r
1percentage area failing the gamma  criteria.
plan was executed to phantom for 30 fractions. In RapidArc
patient treatment, the maximum area of gamma  failing was
5% (Fig. 6, P3) and maximum gamma  was found to be 10.
Thus, from analysing the various source of error, the inter-
fractional anatomical variation was found to be predominant.
For patient P1 the maximum gamma  values found to be less
than 2 whereas the area gamma  failing criteria is 1.5%. This
indicates the minimal movement  of organ or proper ﬁlling of
bladder and rectum produces the lesser variation in the exit
ﬂuence. These results agree with the Lee et al. ﬁndings.23
This study shows the consistency in the patient exit ﬂu-
ence, when treatment positioning was done with the kV
images. The sources of deviation are isolated as much as
possible. However, there are possibilities that some sources
of errors might have gone undetected. This study does not
report the deviations in the patient absolute dose and/or vari-
ation between planned and measured ﬂuence. The patient’s
treatment positioning veriﬁcation was not done with CBCT
images, which may further increase the patient setup accu-
racy. When using exit ﬂuence for dose reconstruction in
patient CT images, the variations due to the MLC  and output
are very small. As the patient related source of error is larger,
the dose reconstruction in the cone beam CT images acquired
before treatment will be an appropriate method to measure
the dose delivered to the patients.
Even with these limitations, portal dose images are used to
verify exit dose variation. If the variations of exit dose images
exceeds the percentage of area gamma failing is more  than 5%,
the treatment has to be analysed by taking the CBCT images
to verify anatomical positions.
6.  Conclusion
The recording and analysis of exit ﬂuence for each fraction
is useful in determining the variation in delivered doses.
By analysing the results, the errors can be minimised and
improve the quality of treatment. The results show that the
1iotherapy 1 7 ( 2 0 1 2 ) 324–331
variation due to interfractional organ motion is greater than
the variation caused by machine related sources. With this
technique, future clinical developments in adaptive radiation
therapy through daily dosimetric measurements of treatment
day images are possible. This will be used to verify the accu-
mulated dose delivered to the patient during the entire course
of treatment.
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